Yang et al., 2019 - Google Patents
Identification of LCN1 as a potential biomarker for breast cancer by bioinformatic analysisYang et al., 2019
- Document ID
- 6200458656223336734
- Author
- Yang Y
- Li F
- Luo X
- Jia B
- Zhao X
- Liu B
- Gao R
- Yang L
- Wei W
- He J
- Publication year
- Publication venue
- DNA and Cell Biology
External Links
Snippet
The biological functions of lipocalin-1 (LCN1) are involved in innate immune responses and act as a physiological scavenger of potentially harmful lipophilic molecules. However, the relevance of LCN1 with cancer is rarely concerned currently. The aim of this study is to …
- 239000000090 biomarker 0 title abstract description 18
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
- C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yang et al. | Identification of LCN1 as a potential biomarker for breast cancer by bioinformatic analysis | |
Yang et al. | Tumor immune microenvironment related gene-based model to predict prognosis and response to compounds in ovarian cancer | |
Liu et al. | Finding new cancer epigenetic and genetic biomarkers from cell-free DNA by combining SALP-seq and machine learning | |
Zheng et al. | The efficacy of different inflammatory markers for the prognosis of patients with malignant tumors | |
Liu et al. | MiR-103a promotes tumour growth and influences glucose metabolism in hepatocellular carcinoma | |
Guo et al. | Expression and clinical significance of miRNA-145 and miRNA-218 in laryngeal cancer | |
Zhou et al. | METTL3 is associated with the malignancy of esophageal squamous cell carcinoma and serves as a potential immunotherapy biomarker | |
Xu et al. | Expression of CLIC1 as a potential biomarker for oral squamous cell carcinoma: a preliminary study | |
Zhu et al. | Effects of immune inflammation in head and neck squamous cell carcinoma: Tumor microenvironment, drug resistance, and clinical outcomes | |
Jiang et al. | Assessment of significant pathway signaling and prognostic value of GNG11 in ovarian serous cystadenocarcinoma | |
Shi et al. | Gene expression signature for detection of gastric cancer in peripheral blood | |
Liang et al. | Comparative proteome identifies complement component 3-mediated immune response as key difference of colon adenocarcinoma and rectal adenocarcinoma | |
Ding et al. | The ratio of preoperative serum biomarkers predicts prognosis in patients with oral squamous cell carcinoma | |
Li et al. | Identification of disulfidptosis-related subtypes, characterization of tumor microenvironment infiltration, and development of a prognosis model in colorectal cancer | |
Luo et al. | Characterization of butyrate-metabolism in colorectal cancer to guide clinical treatment | |
Xiong et al. | Identification of a novel defined inflammation-related long noncoding RNA signature contributes to predicting prognosis and distinction between the cold and hot tumors in bladder cancer | |
Hong et al. | Construction of a ferroptosis scoring system and identification of LINC01572 as a novel ferroptosis suppressor in lung adenocarcinoma | |
He et al. | Clinical and genetic characteristics in pancreatic cancer from Chinese patients revealed by whole exome sequencing | |
Zhang et al. | Construction of lncRNA prognostic model related to cuproptosis in esophageal carcinoma | |
Zheng et al. | Effect of N6-methyladenosine methylation-related gene signature for predicting the prognosis of hepatocellular carcinoma patients | |
Lin et al. | RAGE is a potential biomarker implicated in immune infiltrates and cellular senescence in lung adenocarcinoma | |
Su et al. | Stratification of ovarian cancer patients from the prospect of drug target-related transcription factor protein activity: the prognostic and genomic landscape analyses | |
Guan et al. | Comprehensive analysis of role of cyclin-dependent kinases family members in colorectal cancer | |
Dong et al. | Integrated analysis revealed hypoxia signatures and LDHA related to tumor cell dedifferentiation and unfavorable prognosis in pancreatic adenocarcinoma: Hypoxia in PDAC | |
Xu et al. | Impact of ferroptosis-related risk genes on macrophage M1/M2 polarization and prognosis in glioblastoma |